Detalles de la búsqueda
1.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38451052
2.
Paediatric indications and dosing guidance for advanced targeted treatments in Australia.
Australas J Dermatol
; 2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38445760
3.
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Considerations for paediatric patients.
Australas J Dermatol
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38741474
4.
Bimekizumab maintenance of response through 3â years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Br J Dermatol
; 188(6): 749-759, 2023 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36967713
5.
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Br J Dermatol
; 189(6): 685-694, 2023 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37562034
6.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 89(2): 274-282, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37019386
7.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115523
8.
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
J Am Acad Dermatol
; 89(5): 911-919, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37019385
9.
The Treat-to-Target Project in Atopic Dermatitis: One Year On.
Acta Derm Venereol
; 103: adv5382, 2023 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37083095
10.
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients.
Australas J Dermatol
; 64(4): 476-487, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37501636
11.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet
; 397(10273): 475-486, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549192
12.
Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
Brain
; 144(4): 1183-1196, 2021 05 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33880507
13.
Method of Assessing Skin Cancerization and KeratosesTM (MASCK™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization.
Clin Exp Dermatol
; 47(6): 1144-1153, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35150158
14.
Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.
Australas J Dermatol
; 63(3): 312-320, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35816576
15.
Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Australas J Dermatol
; 63(3): 303-311, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35809080
16.
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.
Australas J Dermatol
; 63(4): 421-436, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36125089
17.
Babesia vulpes in a dog from Prince Edward Island, Canada.
Can Vet J
; 63(6): 589-592, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35656526
18.
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
N Engl J Med
; 379(14): 1313-1321, 2018 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30205746
19.
Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital.
Dermatol Ther
; 34(6): e15128, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34505752
20.
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Acta Derm Venereol
; 101(11): adv00585, 2021 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34618162